PTO/S8/06a (07-09)
Approved for use through 07/31/2012. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute	for form 1449A/PTO			Complete if Known		
				Application Number	10/594,923	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Filing Date	05-02-07	
				First Named Inventor	Naohisa TACHIYA	
				Art Unit	1621	
				Examiner Name	Peter G O'SULLIVAN	
Sheet	1	of	2	Attorney Docket Number	Q97359	

U.S. PATENT DOCUMENTS							
Examiner initial *	Cite	Document Number	Publication Date	Name of Patentee or	Pages, columns, Lines, Where		
initial "	No.	Number - Kind Code 2 (if known)	MM-DD-YYYY Applicant of Cited Document		Relevant Passages or Relevant Figures Appear		

	ļ			***************************************			

				······			
***************************************				***************************************			
***************************************	ļ		***************************************				
***************************************				***************************************			
***************************************			***************************************				
	ļ						
	ļ			***************************************			
	ļ						

FOREIGN PATENT DOCUMENTS							
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, columns, Lines, Where Relevant Passages or Relevant		
Initial *	No. 1	Country ³ Number ⁴ Kind Code (if known) ⁵	MM-DD-YYYY	Applicant of Cited	-		
		Code (Inclown)		Document	Figures Appear	Т	
	1	CA 2 561 050 - A1	10-06-2005	PHOTOCURE ASA			
				1			
			***************************************	***************************************			
	·····			<u> </u>		i i i i i i i i i i i i i i i i i i i	
1							

Examiner Signature		Date Considered	
* EXAMINER: In	itial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line thro	ough citation if not i	n conformance and not

Considered Include copy of this form with near communication to applicant. 1. Applicant's unique citation design number (optional), 2 See Kinds Coder of LSPTO patient Documents at www.supto.gov on WPEP 901.04. 3. Enter Office that insued the document, by the take letter code (WPPO Standard ST.3), 4. For Jagonese patient document, the Indication of the year of the riging of the Emperor must precede the senial number of the patient document. 5. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6. Applicant is to place a check mark here if English language Transitation is statistics.

This collection of information is required by 37 CFR 1 37 and 1.90. The information is required to obtain or retain a benefit by the public which is to 16 (in (ind by the USPTO is process) and spicialisms. Confidentially is governed by 38 US. C.12 and 37 CFR 1.14. This collection is estimated to be 42 Posts to compile, including aphening, pressing, and submitting the completed application from the USPTO. There will vary depending upon the individual case. My comments on the amount of time you require to complete this form and/or suppressions for reducing the bluends, should be sent to the Cell infloration Officer, U.S. Patert and Tradems's Office, P.O. Bost 1453. Alexandris, W. 22231-1450. DO NOT SIND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Commissions for Patents, P.O. Bost 1459. Alexandris, W. 22231-1450.

Approved for use through 07/31/2012. OMB 0851-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

_	OIIC	Jei tile Paperwork leduc	ANTIMAL	or 1995, no persons are requi	area to respond to a correction of information unless it contains a valid onto control infinitely			
INFORMATION DISCLOSURE					Complete if Known			
					Application Number	10/594,923		
					Filing Date	05-02-07		
	SIAII	LIVILIA I DI	AFF	LICANI	First Named Inventor	Naohisa TACHIYA		
	(U	se as many sheets a	s neces	sary)	Art Unit	1621		
	,				Examiner Name	Peter G O'SULLIVAN		
	Sheet	eet 2 of 2		2	Attorney Docket Number	Q97359		
		1	1)		

Linder the Department reduction Act of 1005, no namena are re-

		NON PATENT LITERATURE DOCUMENTS	
Examiner initial *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the kern (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
	2	BAXTER et al., "Evidence for Specific Lead-delta-aminolevulinate Complex Formation by Carbon-13 Nuclear Magnetic Resonance Spectroscopy," Toxicology and Applied Pharmacology, 1979, pp. 477-482, Vol. 47	
	3	Communication dated January 17, 2012, issued by the Canadian Intellectual Property Office in corresponding Canadian Patent Application No. 2,562,170	
	•		
			ļ
			-

Examiner Signature		Date Considered					
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not							

considered Include copy of this form with next communication to applicant.

^{1.} Applicants unique citation designation number. (optional) 2. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is expirited by 37 CFR 13 and 198. The information is required to obtain or retain a benefit by the public which is to Tit (and right to be process) an application. Confedentially is generated by 36 LISs CFL 22 and 37 CFR 11.4 in confection is entirelated to blaze 2 brus to comprete, including symbol process. The confedential process to blaze 2 brus to comprete, including symbol process. The confedential process of the confedential process of

INFORMATION DISCLOSURE CERTIFICATION STATEMENT

Application Number	10/594,923
Filing Date	May 2, 2007
First Named Inventor	Naohisa TACHIYA
Group Art Unit	1621
Examiner Name	Peter G O'SULLIVAN
Attorney Docket Number	Q97359

	ee 37 CFR 1.97 and 1.98 to make the appropriate sele	ropriate	selection
--	--	----------	-----------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.79(e)(2).

That each item of information contained in the Information Disclosure Statement filed concurrently herewith: (i) was first cited in any communication from a patent office in a counterpart foreign or international application or from the Office, and this communication was not received by any individual designated in § 1.56(c) more than thirty days

prior to the filing of the Information Disclosure Statement, or (ii) is a communication that was issued by a patent office in a counterpart foreign or international application or by the Office, and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement. See 37 CFR 1.704(d).

- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.
- □ None

SUGHRUE MION, PLLC 2100 Pennsylvania Avenue, N.W. Washington, DC 20037 Telephone: (202) 293-7060 Facsimile: (202) 293-7860

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Hui C. Wauters/	Date	February 16, 2012
Name/Print	Hui C. Wauters	Registration Number	57.426